Statin use and risk of prostate cancer: Results from a population-based epidemiologic study

Ilir Agalliu, Claudia A. Salinas, Philip D. Hansten, Elaine A. Ostrander, Janet L. Stanford

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002-2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95% CI: 0.7, 1.8 for >10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI ≥30 kg/m2) who used statins had an increased risk (OR = 1.5, 95% CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95% CI: 1.1, 3.0 for ≥5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.

Original languageEnglish (US)
Pages (from-to)250-260
Number of pages11
JournalAmerican Journal of Epidemiology
Volume168
Issue number3
DOIs
StatePublished - Aug 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Epidemiologic Studies
Prostatic Neoplasms
Odds Ratio
Population
Confidence Intervals
Body Mass Index
Logistic Models

Keywords

  • Case-control studies
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Obesity
  • Odds ratio
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Epidemiology

Cite this

Statin use and risk of prostate cancer : Results from a population-based epidemiologic study. / Agalliu, Ilir; Salinas, Claudia A.; Hansten, Philip D.; Ostrander, Elaine A.; Stanford, Janet L.

In: American Journal of Epidemiology, Vol. 168, No. 3, 08.2008, p. 250-260.

Research output: Contribution to journalArticle

Agalliu, Ilir ; Salinas, Claudia A. ; Hansten, Philip D. ; Ostrander, Elaine A. ; Stanford, Janet L. / Statin use and risk of prostate cancer : Results from a population-based epidemiologic study. In: American Journal of Epidemiology. 2008 ; Vol. 168, No. 3. pp. 250-260.
@article{a043f51de5c64e6092d5e363f2c4b977,
title = "Statin use and risk of prostate cancer: Results from a population-based epidemiologic study",
abstract = "Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002-2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95{\%} confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95{\%} CI: 0.7, 1.8 for >10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI ≥30 kg/m2) who used statins had an increased risk (OR = 1.5, 95{\%} CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95{\%} CI: 1.1, 3.0 for ≥5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.",
keywords = "Case-control studies, Hydroxymethylglutaryl-CoA reductase inhibitors, Obesity, Odds ratio, Prostatic neoplasms",
author = "Ilir Agalliu and Salinas, {Claudia A.} and Hansten, {Philip D.} and Ostrander, {Elaine A.} and Stanford, {Janet L.}",
year = "2008",
month = "8",
doi = "10.1093/aje/kwn141",
language = "English (US)",
volume = "168",
pages = "250--260",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Statin use and risk of prostate cancer

T2 - Results from a population-based epidemiologic study

AU - Agalliu, Ilir

AU - Salinas, Claudia A.

AU - Hansten, Philip D.

AU - Ostrander, Elaine A.

AU - Stanford, Janet L.

PY - 2008/8

Y1 - 2008/8

N2 - Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002-2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95% CI: 0.7, 1.8 for >10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI ≥30 kg/m2) who used statins had an increased risk (OR = 1.5, 95% CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95% CI: 1.1, 3.0 for ≥5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.

AB - Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002-2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95% CI: 0.7, 1.8 for >10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI ≥30 kg/m2) who used statins had an increased risk (OR = 1.5, 95% CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95% CI: 1.1, 3.0 for ≥5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.

KW - Case-control studies

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Obesity

KW - Odds ratio

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=47649118548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649118548&partnerID=8YFLogxK

U2 - 10.1093/aje/kwn141

DO - 10.1093/aje/kwn141

M3 - Article

C2 - 18556686

AN - SCOPUS:47649118548

VL - 168

SP - 250

EP - 260

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 3

ER -